Medicare adds cancer blood tests—but only for seniors 68 and up, at first

What it does

This bill amends Medicare to cover multi-cancer early detection screening tests (blood tests that screen for multiple cancer types at once) starting January 1, 2028. Medicare will pay for these tests using the same reimbursement rate as existing stool-based DNA screening tests, with age-based eligibility starting at 68 and increasing by one year annually, and a limit of one test per individual per year. The bill requires FDA clearance or approval and CMS determination that the test is 'reasonable and necessary,' and exempts tests rated A or B by the U.S. Preventive Services Task Force from age and frequency limits.

Why we flagged it

The bill's core function is straightforward: it adds a new covered service to Medicare with defined payment rates and eligibility rules. The named-after-person framing (Nancy Gardner Sewell) is commemorative but does not alter the bill's substantive mechanism, which is a standard coverage amendment.

What the text implies

• CMS retains sole discretion to determine whether a test is 'reasonable and necessary' without explicit clinical-evidence thresholds in the statute, creating regulatory uncertainty and potential for inconsistent coverage decisions across test manufacturers.
• The phased age-eligibility ramp (68 in 2028, 69 in 2029, etc.) creates a multi-year period where younger seniors (65–67) are excluded despite potentially benefiting from early cancer detection, raising equity questions about why age-based rationing was chosen over risk-based or universal eligibility.
• Payment is pegged to the stool DNA screening test rate through 2030, then transitions to 'lesser of' the old rate or a new rate determined under section 1834A—creating a cliff-edge payment change in 2031 that could affect test availability or manufacturer participation.
• The bill does not restrict use of multi-cancer tests as diagnostic follow-ups to abnormal results from traditional cancer screenings (breast, colorectal, etc.), potentially creating incentives for cascading testing and higher Medicare spending without explicit cost-containment language.
• USPSTF grade A or B ratings automatically exempt tests from age and frequency limits, meaning a single favorable USPSTF recommendation could unlock unlimited coverage for all Medicare beneficiaries regardless of age—a significant budget exposure not quantified in the bill.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicare beneficiaries gain access to a potentially valuable early cancer detection tool at no out-of-pocket cost (covered by Medicare), which could improve health outcomes through earlier diagnosis. However, the bill's effectiveness depends entirely on whether these tests are clinically validated and cost-effective—a determination delegated to CMS without explicit performance standards—and the phased age eligibility (starting at 68, rising annually) delays access for younger seniors, creating a

Who stands to gain

• in vitro diagnostic (IVD) manufacturers developing multi-cancer blood tests
• genomic sequencing companies
• clinical laboratory service providers
• healthcare systems and oncology practices offering screening services

Named in the bill

Centers for Medicare & Medicaid Services (CMS), U.S. Preventive Services Task Force (USPSTF), Food and Drug Administration (FDA), Medicare Part A and Part B, Bristol Myers Squibb (BMY), Guardant Health (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ)

Where it stands

338 cosponsors: 185 Democrats, 152 Republicans, 1 Independents.

• Jan 31, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jan 31, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”
• Sep 17, 2025 — Markup held in committee · Congress.gov: “Committee Consideration and Mark-up Session Held”
• Sep 17, 2025 — Reported out of committee · Congress.gov: “Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 43 - 0”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

19 lobbying clients named this bill on 25 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $10,369,304 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 96% of bills with at least one filing.

Jodey Arrington, the sponsor, reported $573,000 in PAC receipts in the 2026 cycle.

• America's Health Insurance Plans Inc (ahip) — $3,010,000 on 1 filing
• American Cancer Society Cancer Action Network Inc — $2,380,000 on 1 filing
• Grail, Inc. (formerly Grail, Llc) — $1,260,000 on 2 filings
• American Association of Nurse Practitioners — $950,000 on 2 filings
• John Hancock Life Insurance Company (u.s.a) — $850,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.